ReviewBreast cancer (Dove Medical Press)2014
Current strategies for the prevention of breast cancer.
Review in Breast cancer (Dove Medical Press), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assessing and improving communication strategies among healthcare providers and African American individuals with systemic lupus: a scoping review.BMC rheumatology · 2026Pooled it
- Risk-reducing medications for primary breast cancer: a network meta-analysis.The Cochrane database of systematic reviews · 2019Pooled it
- Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.Research square · 2023Article
- Applied Machine Learning in Spiral Breast-CT: Can We Train a Deep Convolutional Neural Network for Automatic, Standardized and Observer Independent Classification of Breast Density?Diagnostics (Basel, Switzerland) · 2022Article
- Multichannel DenseNet Architecture for Classification of Mammographic Breast Density for Breast Cancer Detection.Frontiers in public health · 2022Article
- Intermammary breast cancer; the first reported case.International journal of surgery case reports · 2021Article
- Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues.Clinical and experimental reproductive medicine · 2021Article
- Article
- Looking beyond the Lamppost: Population-Level Primary Prevention of Breast Cancer.International journal of environmental research and public health · 2020Article
- Influence of breast cancer risk factors and intramammary biotransformation on estrogen homeostasis in the human breast.Archives of toxicology · 2020Article
- Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View.International journal of molecular sciences · 2020Review
- Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer.Reproductive medicine and biology · 2019Article
- Determination of mammographic breast density using a deep convolutional neural network.The British journal of radiology · 2019Article
- Editorial comment: cone-beam and phase contrast CT: new horizons in breast imaging?European radiology · 2018Article
- ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.Cancer research · 2018Article
- Understanding breast cancer - The long and winding road.BBA clinical · 2017Review
- Breast cancer trends differ by ethnicity: a report from the South African National Cancer Registry (1994-2009).European journal of public health · 2017Article
- Prevalence of chemopreventive agent use among hospitalised women at high risk for breast cancer: a cross-sectional study.BMJ open · 2016Article
- Cytotoxicity, Post-Treatment Recovery, and Selectivity Analysis of Naturally Occurring Podophyllotoxins from Bursera fagaroides var. fagaroides on Breast Cancer Cell Lines.Molecules (Basel, Switzerland) · 2016Article
- FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness.Carcinogenesis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the high incidence of breast cancer in the United States, optimal strategies for its prevention are imperative. This entails identification of women who are at an increased risk for breast cancer and an integrative approach that includes effective screening methods as well as nutritional, pharmacologic, and surgical management. Several breast cancer risk-assessment tools, such as the Gail and Claus models, can help clinicians determine the quantitative risk of breast cancer. The role of selective estrogen receptor modulators, such as tamoxifen and raloxifene, for the prevention of breast cancer has been well established. Several other agents, such as aromatase inhibitors, are currently being investigated. The potential adverse effects of these chemopreventive agents, which include an impact on the quality of life, must be discussed with the patient before deciding on this approach. Additionally, breast cancer risk factors have been identified over the years; some of them are modifiable, but others are not. Although there is no conclusive evidence to suggest the protective role of specific dietary components, alcohol consumption and obesity are associated with an increased breast cancer risk; thus lifestyle changes can lead to a lower risk of developing breast cancer. Surgical approaches, including bilateral risk-reduction mastectomy and salpingo-oophorectomy, are usually limited to women with a hereditary predisposition to development of breast cancer. The objective of this review is to summarize the various approaches directed at reducing the incidence of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.